Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates [Yahoo! Finance]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Yahoo! Finance
The company had incurred a loss of 46 cents per share in the year-ago quarter. Total revenues, comprising product sales and grant revenues, came in at $144.9 million compared with $95.3 million reported in the year-ago period. The top line beat the Zacks Consensus Estimate of $141.9 million. Quarter in Detail Caplyta, the only approved drug in Intra-Cellular's portfolio, was approved by the FDA in December 2019, for treating schizophrenia in adults. The drug also received the FDA's approval for treating bipolar depression in December 2021. Post this approval, Caplyta sales have increased tremendously. Net product revenues, comprising Caplyta sales, were up 53% year over year to $144.8 million on the back of strong prescription uptake. Per Intra-Cellular, Caplyta prescriptions jumped 39% year over year, despite typical first-quarter seasonal dynamics as well as industry disruption. Research and development (R&D) expenses climbed 13% to $42.8 million from the year-ago quarte
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its First-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $90.00 price target on the stock.MarketBeat
ITCI
Earnings
- 5/7/24 - Beat
ITCI
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/29/24 - Form ARS
- ITCI's page on the SEC website